Source: Frontiers in Immunology, by Peterson, Milene; Hunter, Joe G. L.; Gatalica, Zoran; Rose, Inga; Stafford, Phillip; Diehnelt, Chris W. (September 3, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- A 108-peptide microarray spanning nine EBV proteins was analytically tested using 329 serum and plasma specimens.
- Composite scores for EBNA-1, VCA-p18, and EA-D correlated with ELISA, while Streck plasma selectively reduced IgM signals.
- The proof-of-concept cohort analysis did not establish a simple EBV antibody signature that distinguishes multiple sclerosis.
Researchers at Robust Diagnostics, Reference Medicine, and Arizona State University have analytically validated a peptide microarray that profiles antibody responses to Epstein-Barr virus, or EBV, at far finer detail than conventional blood tests. The array contains 108 short protein fragments, called peptides, drawn from nine EBV proteins, and was tested on 329 blood-derived specimens. It produced reproducible results within an experimental run and across separate slides, while composite scores for several EBV antigens tracked with standard enzyme-linked immunosorbent assay, or ELISA, measurements. The work also tested whether the assay behaves consistently in serum, EDTA plasma, and plasma collected in Streck cell-free DNA tubes. Immunoglobulin G, or IgG, antibody signals remained stable among those sample types, but immunoglobulin M, or IgM, signals fell selectively in Streck plasma. In exploratory comparisons involving infectious mononucleosis, multiple sclerosis, and non-multiple-sclerosis donors, the platform detected broad EBV antibody reactivity and reproduced a previously noted pattern involving the end of the EBNA-1 protein. Yet overall EBV reactivity did not separate people with multiple sclerosis from those without it, reinforcing that this is a research tool for resolving immune responses rather than a diagnostic test for multiple sclerosis.
A higher-resolution view of EBV antibodies
EBV is a herpesvirus that infects more than 95% of adults and persists for life, usually quietly, in B cells, a type of immune cell. Most infections cause no obvious illness, but EBV causes infectious mononucleosis and is linked to several cancers and autoimmune conditions, including multiple sclerosis.
Standard EBV serology commonly measures antibodies against a limited set of whole viral proteins, including EBNA-1, viral capsid antigen, and early antigen-D. That approach is useful for assessing exposure and stages of infection, but it treats each large protein as one target. It cannot show which specific stretches of a protein a person's antibodies recognize.
How the peptide microarray works
A peptide microarray works a little like a wall covered with tiny, carefully labeled locks. Each peptide is a short linear section of a viral protein, and antibodies in a blood sample can bind to the matching peptide targets. Measuring those binding events creates a detailed map of antibody recognition.
The validated array used 108 peptides spanning nine major EBV antigens. Because it presents many peptide targets at once, it can capture patterns of immune recognition across the virus rather than collapsing all binding to one protein into a single number. The method is semi-quantitative, meaning it compares the strength of antibody signals without necessarily providing an absolute concentration for every antibody.
Testing analytical performance
For a laboratory platform to be useful in translational research, it has to provide dependable measurements before researchers can interpret biological differences. The team evaluated reproducibility within a block of samples and between separate microarray slides, along with detection thresholds and the minimum fold-change the platform could detect.
Those performance measures were consistent with established peptide-array benchmarks. The researchers also combined peptide-level signals into antigen-level scores and compared them with conventional ELISA testing. Scores for EBNA-1, VCA-p18, and EA-D correlated with their corresponding ELISA assays, connecting the detailed peptide readout with familiar clinical serology targets.
Why blood collection tubes matter
Clinical samples do not all begin in the same tube, and that detail can change what an antibody test detects. The study included serum, K2 EDTA plasma, and plasma from Streck cell-free DNA collection tubes, which contain formaldehyde-releasing stabilizers designed to preserve nucleic acids.
IgG signals were stable across the collection matrices tested. IgM signals, however, were selectively attenuated in Streck plasma. IgM is often associated with more recent immune responses, so the finding matters for studies that intend to use IgM as a primary readout: fixative-containing Streck tubes require caution for that purpose.
What the disease-cohort analysis found
The researchers applied the array to specimens from donors with infectious mononucleosis, multiple sclerosis, and no multiple sclerosis diagnosis. Across those groups, the assay consistently detected broad humoral reactivity, meaning antibody responses, to EBV. That result supports its use for studying the many ways people recognize different parts of the virus.
The proof-of-concept analysis also recapitulated biologically relevant reactivity to the C-terminal region, or tail end, of EBNA-1. Prior work has associated this region with molecular mimicry in multiple sclerosis, a proposed process in which an immune response to a viral target can also react with a similar human target. However, the broader array-wide EBV response did not yield a simple antibody signature that distinguished the multiple sclerosis cohort from the non-multiple-sclerosis cohort.
Why This Matters
That last result is important because EBV exposure itself is extremely common. A platform that measures whether a person has EBV-directed antibodies will often be measuring a shared history of infection, not necessarily a disease-specific biological signal. In this dataset, only a very small set of EBV epitopes, or antibody-recognized protein segments, showed an association with cohort status.
The value of the microarray is therefore its resolution. It can help researchers ask whether two people with similar conventional EBV test results actually recognize different parts of the virus, and whether those differences relate to infectious mononucleosis, autoimmunity, cancer research, or other outcomes. Its analytical characterization also provides practical guidance on which specimen types can be compared and where IgM measurements may be vulnerable to collection-tube effects.
Next steps for peptide-level EBV serology
The platform is positioned for translational research rather than immediate clinical diagnosis. Future studies can use the validated assay in larger and more deeply characterized cohorts to test whether particular peptide-level responses predict disease risk, reflect immune history, or reveal meaningful differences among patient groups. Those efforts will need to separate signals related to near-universal EBV exposure from the narrower patterns that may matter for specific diseases.